408 related articles for article (PubMed ID: 35359087)
21. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy].
Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167
[No Abstract] [Full Text] [Related]
22. [Postoperative complications and their influence on the prognosis factors in gastric cancer patients receiving neoadjuvant treatment].
Wang TB; Mao QK; Zhang XJ; Zhou H; Guo CG; Chen YT; Zhao DB
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):160-166. PubMed ID: 33508922
[No Abstract] [Full Text] [Related]
23. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial.
Ychou M; Rivoire M; Thezenas S; Quenet F; Delpero JR; Rebischung C; Letoublon C; Guimbaud R; Francois E; Ducreux M; Desseigne F; Fabre JM; Assenat E
Ann Surg Oncol; 2013 Dec; 20(13):4289-97. PubMed ID: 23955585
[TBL] [Abstract][Full Text] [Related]
24. Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases.
Samaras P; Breitenstein S; Haile SR; Stenner-Liewen F; Heinrich S; Feilchenfeldt J; Renner C; Knuth A; Pestalozzi BC; Clavien PA
Ann Surg Oncol; 2011 Jul; 18(7):1924-31. PubMed ID: 21207165
[TBL] [Abstract][Full Text] [Related]
25. Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort.
Rouyer M; Smith D; Laurent C; Becouarn Y; Guimbaud R; Michel P; Tubiana-Mathieu N; Balestra A; Jové J; Robinson P; Noize P; Moore N; Ravaud A; Fourrier-Réglat A;
Target Oncol; 2016 Feb; 11(1):83-92. PubMed ID: 26298481
[TBL] [Abstract][Full Text] [Related]
26. Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study).
Folprecht G; Gruenberger T; Bechstein W; Raab HR; Weitz J; Lordick F; Hartmann JT; Stoehlmacher-Williams J; Lang H; Trarbach T; Liersch T; Ockert D; Jaeger D; Steger U; Suedhoff T; Rentsch A; Köhne CH
Ann Oncol; 2014 May; 25(5):1018-25. PubMed ID: 24585720
[TBL] [Abstract][Full Text] [Related]
27. [Analysis of factors related to the prognostic benefit of neoadjuvant chemotherapy followed by interval debulking surgery in patients with advanced ovarian cancer].
Wang DF; Zhang GN; Peng CR; Shi Y; Shi XW
Zhonghua Fu Chan Ke Za Zhi; 2021 Jun; 56(6):385-392. PubMed ID: 34154313
[No Abstract] [Full Text] [Related]
28. [Evaluation value of preoperative peripheral blood lymphocyte-to-monocyte ratio on the prognosis of patients with stage III colon cancer].
Chen J; Peng J; Fan W; Zhang R; Wang F; Zhou W; Xu D; Pan Z; Lu Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):73-78. PubMed ID: 30703797
[TBL] [Abstract][Full Text] [Related]
29. Prognosis of a Heterogeneous TRG Pathological Response to Neoadjuvant Chemotherapy in Patients who Undergo Resection for Colorectal Liver Metastases.
Laroche S; Scatton O; Charlotte F; Bachet JB; Lim C; Fuks D; Goumard C
Ann Surg Oncol; 2024 Jul; 31(7):4436-4444. PubMed ID: 38549003
[TBL] [Abstract][Full Text] [Related]
30. Outcome of microscopic incomplete resection (R1) of colorectal liver metastases in the era of neoadjuvant chemotherapy.
Ayez N; Lalmahomed ZS; Eggermont AM; Ijzermans JN; de Jonge J; van Montfort K; Verhoef C
Ann Surg Oncol; 2012 May; 19(5):1618-27. PubMed ID: 22006375
[TBL] [Abstract][Full Text] [Related]
31. Effect of Time to Surgery of Colorectal Liver Metastases on Survival.
Chen EY; Mayo SC; Sutton T; Kearney MR; Kardosh A; Vaccaro GM; Billingsley KG; Lopez CD
J Gastrointest Cancer; 2021 Mar; 52(1):169-176. PubMed ID: 32086781
[TBL] [Abstract][Full Text] [Related]
32. Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial.
Katipally RR; Martinez CA; Pugh SA; Bridgewater JA; Primrose JN; Domingo E; Maughan TS; Talamonti MS; Posner MC; Weichselbaum RR; Pitroda SP;
JAMA Oncol; 2023 Sep; 9(9):1245-1254. PubMed ID: 37471075
[TBL] [Abstract][Full Text] [Related]
33. Impact of Postoperative Infectious Complications on Long-Term Outcomes for Patients Undergoing Simultaneous Resection for Colorectal Cancer Liver Metastases: A Propensity Score Matching Analysis.
Chen Q; Deng Y; Chen J; Zhao J; Bi X; Zhou J; Li Z; Huang Z; Zhang Y; Chen X; Zhao H; Cai J
Front Oncol; 2021; 11():793653. PubMed ID: 35071001
[TBL] [Abstract][Full Text] [Related]
34. [Clinical Application of Microwave Ablation in Potentially Resectable Colorectal Cancer With Simultaneously Multiple Liver Metastases].
Han L; Wu XL; Guo F; Xi YN; Chang XY; Zhang CZ; Zhang JF; Ma PC
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2024 Apr; 46(2):161-168. PubMed ID: 38686711
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy Plus Bevacizumab as Neoadjuvant or Conversion Treatment in Patients with Colorectal Liver Metastases.
García-Alfonso P; Cavanagh Podesta M; Muñoz Martín A; Blanco Codeisido M; Calvo A; Peligros I; Corcuera A; Belén Rúperez Blanco A; Custodio-Cabello S; López Trabada D; Martín M; DE Ramón E
Anticancer Res; 2018 May; 38(5):3069-3077. PubMed ID: 29715142
[TBL] [Abstract][Full Text] [Related]
36. Changes in serum lactate dehydrogenase levels as markers of pathological response and prognosis in colorectal liver metastases patients receiving neoadjuvant chemotherapy followed by resection.
Chen J; Chen Q; Yao J; Jiang Y; Zhou J; Zhao H; Cai J
Ann Palliat Med; 2021 Oct; 10(10):10276-10292. PubMed ID: 34551571
[TBL] [Abstract][Full Text] [Related]
37. Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial.
Mulcahy MF; Mahvash A; Pracht M; Montazeri AH; Bandula S; Martin RCG; Herrmann K; Brown E; Zuckerman D; Wilson G; Kim TY; Weaver A; Ross P; Harris WP; Graham J; Mills J; Yubero Esteban A; Johnson MS; Sofocleous CT; Padia SA; Lewandowski RJ; Garin E; Sinclair P; Salem R;
J Clin Oncol; 2021 Dec; 39(35):3897-3907. PubMed ID: 34541864
[TBL] [Abstract][Full Text] [Related]
38. Role of Predictive Value of the Modified Glasgow Prognostic Score for Later-line Chemotherapy in Patients With Metastatic Colorectal Cancer.
Tsuchihashi K; Ito M; Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama A; Denda T; Satake H; Suto T; Sugimoto N; Katsumata K; Ishikawa T; Kashiwada T; Oki E; Komatsu Y; Okuyama H; Sakai D; Ueno H; Tamura T; Yamashita K; Kishimoto J; Shimada Y; Baba E
Clin Colorectal Cancer; 2018 Dec; 17(4):e687-e697. PubMed ID: 30149986
[TBL] [Abstract][Full Text] [Related]
39. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
40. Obesity is an independent prognostic factor of decreased pathological complete response to neoadjuvant chemotherapy in breast cancer patients.
Karatas F; Erdem GU; Sahin S; Aytekin A; Yuce D; Sever AR; Babacan T; Ates O; Ozisik Y; Altundag K
Breast; 2017 Apr; 32():237-244. PubMed ID: 27318645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
